文献速递胃肠动力与功能性疾病

综述:低FODMAP饮食在肠易激综合征患者中的实施——未来研究方向

Review article: implementation of a diet low in FODMAPs for patients with irritable bowel syndrome-directions for future research.
PubMed 文献 · Aliment Pharmacol Ther · 2019-01-01

本文通过检索Ovid Medline、CINAHL、Scopus和PubMed(从建库至2018年9月)的文献,综述低FODMAP饮食在肠易激综合征患者临床实施中的问题。文章指出应答预测因素仍在研究中,初步数据支持粪便微生物群或粪便挥发性有机化合物谱分析;临床医生培训、患者教育标准及应用程序的作用需正式评估;长期疗效和安全性数据有限。结论认为实施及长期安全性有效性方面仍有许多空白需进一步研究。

要点

  • 低FODMAP饮食对肠易激综合征有效,但临床实施中许多问题未解答。
  • 应答预测因素尚在研究中,初步数据支持粪便微生物群或挥发性有机化合物谱分析。
  • 长期疗效和安全性数据有限,需进一步研究。

核心结论

  • 低FODMAP饮食在临床实践中的实施以及长期安全性和有效性仍存在许多空白,需进一步研究。

研究设计与样本

  • 文献综述,检索Ovid Medline、CINAHL、Scopus和PubMed从建库至2018年9月的文献,检索词聚焦于肠易激综合征人群和FODMAP干预。

主要发现

  • 低FODMAP饮食的应答预测因素仍在研究中,初步数据支持粪便微生物群或粪便挥发性有机化合物谱分析。
  • 临床医生培训、患者关于低FODMAP饮食各阶段的教育标准以及应用程序的作用需要正式评估。
  • 关于低FODMAP饮食的长期疗效和安全性数据有限,涉及持续症状控制、对生活质量和医疗资源利用的影响、营养充足性、饮食失调行为的诱发、对粪便微生物群和代谢组学标志物的影响以及随后向临床效果的转化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the efficacy of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) for patients with irritable bowel syndrome, many questions remain unanswered with respect to its clinical implementation. AIM: To review literature to identify, synthesise, and provide direction for future research in the implementation and evaluation of the low FODMAP diet. METHODS: Bibliographical searches were performed in Ovid Medline, CINAHL, Scopus and PubMed from database commencement until September 2018, with search terms focused on the population (irritable bowel syndrome) and intervention of interest (FODMAP). RESULTS: Predictors of response to a low FODMAP diet remain under investigation, with preliminary data supporting faecal microbiota or faecal volatile organic compound profiling. Training of clinicians, and standards for the education of patients about the phases of a low FODMAP diet, as well as the role of Apps, require formal evaluation. There are limited data on the longer term efficacy and safety of the low FODMAP diet with respect to sustained symptom control, effect on quality of life and healthcare utilisation, nutritional adequacy, precipitation of disordered eating behaviours, effects on faecal microbiota and metabolomic markers, and subsequent translation to clinical effects. CONCLUSIONS: Many gaps in implementation of the low FODMAP diet in clinical practice, as well as long-term safety and efficacy, remain for further investigation.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mitchell H, Porter J, Gibson PR, et al. Review article: implementation of a diet low in FODMAPs for patients with irritable bowel syndrome-directions for future research. Aliment Pharmacol Ther. 2019. PMID: 30589971. doi:10.1111/apt.15079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。